Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

WuXi NextCODE in Hunt for $200 Million in Venture Capital

publication date: May 23, 2017
According to a Reuters report, WuXi NextCODE is talking to investors about another fundraising, this one for $200 million. The company, which is part of WuXi AppTec's genomics operation, completed a $75 million Series B round earlier this month. The funding is drawing interest from top-tier investors such as Hillhouse Capital and Sequoia Capital, said Reuters, which attributed the information to two people with direct knowledge of the activity. WuXi hopes to close the latest round in July, Reuters said. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital